StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)

Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%

Johnson & Johnson Pulmonary Hypertension Therapeutic Area Total by Quarter

Pulmonary Hypertension (PH) Therapeutic Area Total — Worldwide sales ($M) ($M)

QuarterlyAnnual

Johnson & Johnson Pulmonary Hypertension Therapeutic Area Total: $897M in Q3 2026, down 19.6% from a year earlier.

Latest, Q3 2026
897
Period ended Sep 30, 2026
Change on a year earlier
-19.6%
1,115 in Q3 2025
History
39 quarters
Since Q1 2017
Sources
31
Documents cited below

Where the Q3 2026 figure comes from

Source: Form 10-Q (filed 2026-10-21) ↗

Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPulmonary Hypertension (PH) Therapeutic Area Total — Worldwide sales ($M) ($M)Year on yearSource
Q3 2026Sep 30, 2026897-19.6%Form 10-Q (filed 2026-10-21) ↗
Q2 2026Jun 28, 20261,143+2.7%Form 10-Q (filed 2026-07-23) ↗
Q1 2026Mar 29, 20261,135+10.7%Form 10-Q (filed 2026-04-22) ↗
Q4 2025Dec 28, 20251,184+8.4%Form 10-K (filed 2026-02-11) ↗
Q3 2025Sep 28, 20251,115+1.2%Form 10-Q (filed 2026-10-21) ↗
Q2 2025Jun 29, 20251,113+7.1%Form 10-Q (filed 2026-07-23) ↗
Q1 2025Mar 30, 20251,025-2.3%Form 10-Q (filed 2026-04-22) ↗
Q4 2024Dec 29, 20241,092+7.4%Form 10-K (filed 2026-02-11) ↗
Q3 2024Sep 29, 20241,102+15.5%Form 10-Q (filed 2025-10-22) ↗
Q2 2024Jun 30, 20241,039+6.9%Form 10-Q (filed 2025-07-24) ↗
Q1 2024Mar 31, 20241,049+20.3%Form 10-Q (filed 2025-04-23) ↗
Q4 2023Dec 31, 20231,017+16.9%Form 10-K (filed 2026-02-11) ↗
Q3 2023Oct 1, 2023954+12.0%Form 10-Q (filed 2024-10-23) ↗
Q2 2023Jul 2, 2023972+15.3%Form 10-Q (filed 2024-07-25) ↗
Q1 2023Apr 2, 2023872+2.3%Form 10-Q (filed 2024-05-01) ↗
Q4 2022Jan 1, 2023870+2.2%Form 10-K (filed 2025-02-13) ↗

Breakdown

What makes up pulmonary Hypertension Therapeutic Area Total

Cite this data

StockData. (2026). Johnson & Johnson Pulmonary Hypertension Therapeutic Area Total ($M), quarterly Q1 2017–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/ta-pulm-hypertension

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.